Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder
| Autor: | S. Aballéa, Clément François, S. A. Montgomery, P. Auquier, N Despiégel, J. Roïz |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Generalized anxiety disorder business.industry Social anxiety General Medicine Citalopram medicine.disease Relapse prevention behavioral disciplines and activities Quality of life (healthcare) Anti-Anxiety Agents mental disorders behavior and behavior mechanisms medicine Escitalopram business Psychiatry psychological phenomena and processes Anxiety disorder medicine.drug |
| Zdroj: | International Journal of Clinical Practice. 62:1693-1702 |
| ISSN: | 1368-5031 |
| DOI: | 10.1111/j.1742-1241.2008.01879.x |
| Popis: | Background: Social anxiety disorder (SAD) is associated with substantial reduction in health-related quality of life (HRQoL). Escitalopram has proven efficacy in the short-term treatment of SAD and prevention of relapse. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|